IDEX Biometrics (IDEX) Q1 2025 earnings summary

Executive summary

• Announced a new strategy focusing on the access market and operational improvements, with a new CEO appointed in Q1 2025.

• Secured a NOK 30 million debt facility, converted to shares post-quarter, and renegotiated convertible bond terms.

• Received new production and sensor orders in Japan, Middle East & Africa, and from DigAware.

• Launched subsequent equity offering and completed debt conversion to strengthen capital structure.

Financial highlights

• Q1 2025 revenue was $0.1 million, down from $0.4 million in Q1 2024.

• Net loss for Q1 2025 was $4.1 million, including a $3.2 million net financial gain and a $4.0 million loss from convertible loan amendments; adjusted net loss was $3.4 million.

• Gross margin on products sold was 27.5%, but overall gross margin was negative due to supplementary shipments.

• Operating cash outflow was $2.7 million, improved from $6.9 million in Q1 2024.

• Cash balance at March 31, 2025, was $1.1 million, with equity at $0.1 million.

Outlook and guidance

• Liquidity remains constrained; existing cash and funding are insufficient for the next 12 months.

• A subsequent offering is expected to add NOK 6 million ($0.6 million) in June, but further funding or revenue is needed by Q3 2025.

• The Board maintains the going concern assumption but notes significant doubt about future viability without additional capital.